Blossomhill Doses First Patient in Expanded Phase 1/2 Solara Trial Cohorts
BlossomHill Therapeutics has initiated dosing in the expansion cohorts of its Phase 1/2 SOLARA trial evaluating BH-30643, a novel...
Scilex CEO to Focus on Semnur’s SP-102 for Sciatica Treatment
Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company, has secured a $20 million private placement to fund the...
Krystal Biotech Focuses on Inhaled KB707 for Non-Small Cell Lung Cancer
Krystal Biotech has prioritized the inhaled formulation of KB707, its redosable gene therapy for solid tumors, based on early...
InnoCare Doses First Patient in Mesutoclax BCL2 Inhibitor Trial for MCL in China
InnoCare Pharma has dosed the first patient in a registrational trial of its BCL2 inhibitor, mesutoclax (ICP-248), for mantle...
Global Knee Replacement Surgery Market to Surpass $16B by 2030
The global knee replacement surgery market is projected to reach $16.17 billion by 2030, expanding at a 6.1% compound...
Septerna Doses First Participants in Sep-631 Phase 1 Trial
Septerna has dosed the first participants in a Phase 1 trial of SEP-631, an oral, selective, small molecule Mas-related...
Evoke Pharma Gimoti Patent Listed in FDA Orange Book
Evoke Pharma has secured a new U.S. patent (No. 12,377,064) for the use of its GIMOTI (metoclopramide) nasal spray...
Chinese Team Enables 24 Type 1 Diabetics to Stop Insulin
A Shenzhen-based medical team reports that 24 patients with Type 1 diabetes (T1DM) have discontinued insulin therapy following treatment...
How Sponsors Can Win or Lose in the 510(k) Strategy Pathway
The start-up team was confident. Their Class II device had promising bench data, strong engineering, and investors eager for...
Chinese Team Enables 24 Patients to Stop Insulin Use: Breakthrough in Type 1 Diabetes Treatment
A Shenzhen-based medical team reports that 24 patients with Type 1 diabetes (T1DM) have discontinued insulin therapy, achieving a...